Using low-level light therapy to treat hair loss from chemotherapy in breast cancer patients
Effect of Helmet Type, Home-use Photobiomodulation Therapy Device for Chemotherapy-induced Alopecia
NA · Chang Gung Memorial Hospital · NCT05397457
This study is testing whether a low-level light therapy device can help women who have lost their hair from chemotherapy for breast cancer to regrow their hair and feel better overall.
Quick facts
| Phase | NA |
|---|---|
| Study type | Interventional |
| Enrollment | 106 (estimated) |
| Ages | 20 Years to 75 Years |
| Sex | Female |
| Sponsor | Chang Gung Memorial Hospital (other) |
| Drugs / interventions | chemotherapy |
| Locations | 1 site (Keelung) |
| Trial ID | NCT05397457 on ClinicalTrials.gov |
What this trial studies
This study investigates the effectiveness of a home-use low-level light therapy device in preventing chemotherapy-induced alopecia (CIA) in women diagnosed with breast cancer. Participants will be women aged 20 to 75 who have recently completed chemotherapy and are experiencing grade 2 CIA. The study aims to assess whether this innovative therapy can improve hair regrowth and overall quality of life for these patients. The approach is based on previous findings that low-level light therapy may be beneficial for hair loss conditions.
Who should consider this trial
Good fit: Ideal candidates for this study are women aged 20 to 75 who have been diagnosed with breast cancer and have recently completed chemotherapy.
Not a fit: Patients with scalp tumors, severe mental illness, or those who have received scalp cooling during chemotherapy may not benefit from this study.
Why it matters
Potential benefit: If successful, this therapy could significantly improve the quality of life for breast cancer patients by reducing the emotional and physical impact of hair loss due to chemotherapy.
How similar studies have performed: While scalp cooling is currently the only verified method for preventing CIA, low-level light therapy has shown promise in other hair loss conditions, suggesting potential for success in this novel application.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Age: 20 to 75 years * Informed Consent as documented by signature. * Able to read and converse in chinese * Female * Diagnosis of breast cancer * They completed chemotherapy no more than 2 weeks * Treatment with neoadjuvant (preoperative) or adjuvant (postoperative) chemotherapy: anthracycline and taxane containing (paclitaxel or docetaxel) chemotherapy regimen. * life expectancy was at least 6 months. * Diagnosed with CIA grade 2 according to Common Terminology Criteria for Adverse Events (CTCAE) Exclusion Criteria: * scalp tumor or melanoma * having any serious mental illness or history, or taking psychotropic drugs * a medical history of dermatosis * severe liver and kidney damage * Pregnancy * Take any of the following medications for 6 months prior to initiation of the study: topical minoxidil, and spironolactone, and topical calcitriol * Receiving scalp cooling during chemotherapy
Where this trial is running
Keelung
- Keelung Chang Gung Memorial Hospital — Keelung, Taiwan (RECRUITING)
Study contacts
- Study coordinator: YUAN-CHIEH YEH, Assistant Professor
- Email: b9005030@gmail.com
- Phone: (02)2431-3131
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: Breast Cancer, Chemotherapy-induced Alopecia